OncoMatch/Clinical Trials/NCT06243003
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
Is NCT06243003 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for sclc,extensive stage.
This study aims to evaluate the safety and efficacy of hippocampal-sparing WBRT combined with SRS as first-line treatment for SCLC patients with brain metastases.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Patients with initial diagnosis of ES-SCLC with brain metastases
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
No prior treatment (treatment-naive required)
Max 0 prior lines
Cannot have received: any antitumor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify